Amylin, human (islet amyloid polypeptide) / Studies

Natural peptide · 37 amino acids · 3,903.3 Da

Amylin, human (islet amyloid polypeptide) studies and research data

PepBank has no study results for Amylin, human (islet amyloid polypeptide) yet. Data as of 2026-10-30.

Searches 0 results and 0 papers. Newer studies from Europe PMC

Results in people

0% of 0 results

Results in animals

0% of 0 results

Results in lab cells

0% of 0 results

From computer models

0% of 0 results

The molecule

Amylin, human (islet amyloid polypeptide) identity

Identifiers, parent molecule, targets and development stage, from curated data.

Human amylin (islet amyloid polypeptide, IAPP) is a 37-residue peptide cut from its precursor (UniProt P10997, residues 34-70), with a Cys2-Cys7 disulfide and a C-terminal tyrosine amide. UniProt describes it as a glucoregulatory hormone that acts through amylin receptors (the calcitonin receptor with RAMP1, 2 or 3) and can also bind the calcitonin receptor alone. The synthetic peptide has the INN amlintide (ChEMBL max_phase 2) and is not approved in the US or EU; pramlintide and cagrilintide are amylin analogues.

Kind: Natural peptide · 37 residues
Identifiers: UniProtP10997 (opens in a new tab)ChEMBLCHEMBL2109025 (opens in a new tab)PubChem CID16132430 (opens in a new tab)UNIIU3U3114NE1 (opens in a new tab)CAS122384-88-7KEGGD02913 (opens in a new tab)
Development: Phase 2Synthetic human amylin (amlintide, code AC-001): ChEMBL CHEMBL2109025 max_phase 2. Not approved. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Amylin receptors (CALCR + RAMP1, RAMP2 or RAMP3)CALCR/RAMP1-3P30988 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)
Calcitonin receptorCALCRP30988 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

37 amino acids · 2 modifications · 1 disulfide bond

H-

KCNTATCATQ

RLANFLVHSS

NNFGAILSST

NVGSNTY

Properties

From identity sources

Formula: C₁₆₅H₂₆₁N₅₁O₅₅S₂
Molecular weight: 3,903.28 g/mol
Monoisotopic mass: 3,900.8636 Da

UniProt P10997(opens in a new tab)retrieved 2026-10-08
GSRS UNII U3U3114NE1(opens in a new tab)retrieved 2026-10-08
PubChem CID 16132430(opens in a new tab)retrieved 2026-10-08
Curated KEGG D02913(opens in a new tab)retrieved 2026-10-08
ChEMBL CHEMBL2109025(opens in a new tab)retrieved 2026-10-08

Calculated from the sequence

pKa set

Average mass: 3,903.32 Da; Sum of ExPASy residue masses + water + C-amide, 1 disulfide · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 3,900.8636 Da; Sum of ExPASy residue masses + water + C-amide, 1 disulfide · ExPASy FindMod
Isoelectric point (pI): 11.70; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 3.05; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.097; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 1,490 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp: ExPASy reports more than 10 % error without Trp.
Extinction coefficient, 280 nm (all Cys as cystines): 1,615 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 1.94; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; 40 or below: classed as stable (ExPASy).
Aliphatic index: 68.6; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.49 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.484; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 11.70Bjellqvist (ExPASy) 11.17IPC peptide 11.61IPC protein 11.36

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 11.70 · Net charge at pH 7.4: 3.05

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, C-amide, 1 disulfide. Calculated, not measured.

Show as table

pH	Net charge
0	4.00
1	4.00
2	4.00
3	4.00
4	4.00
5	3.97
6	3.76
7	3.21
8	2.82
9	2.20
10	1.46
11	0.47
12	−0.17
13	−0.75
14	−0.97

Composition

Hydrophobic27% (10)A I L V
Aromatic8% (3)F Y
Positive8% (3)H K R
Polar46% (17)N Q S T
Special11% (4)C G

37 residues. Each residue counts in one class; F and W count as aromatic.

A Ala4 · 11%

I Ile1 · 3%

L Leu3 · 8%

M Met0 · 0%

V Val2 · 5%

F Phe2 · 5%

W Trp0 · 0%

Y Tyr1 · 3%

H His1 · 3%

K Lys1 · 3%

R Arg1 · 3%

D Asp0 · 0%

E Glu0 · 0%

N Asn6 · 16%

Q Gln1 · 3%

S Ser5 · 14%

T Thr5 · 14%

C Cys2 · 5%

G Gly2 · 5%

P Pro0 · 0%

3D structure

PredictedAlphaFold DB · P10997

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Amylin, human (islet amyloid polypeptide) has 37 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 16132430(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.198
μH, best 11-residue window: 0.484
Arrow direction: 46°
Residues: 37 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	K	0°	-1.50
2	C	100°	0.29
3	N	200°	-0.78
4	T	300°	-0.05
5	A	40°	0.62
6	T	140°	-0.05
7	C	240°	0.29
8	A	340°	0.62
9	T	80°	-0.05
10	Q	180°	-0.85
11	R	280°	-2.53
12	L	20°	1.06
13	A	120°	0.62
14	N	220°	-0.78
15	F	320°	1.19
16	L	60°	1.06
17	V	160°	1.08
18	H	260°	-0.40
19	S	0°	-0.18
20	S	100°	-0.18
21	N	200°	-0.78
22	N	300°	-0.78
23	F	40°	1.19
24	G	140°	0.48
25	A	240°	0.62
26	I	340°	1.38
27	L	80°	1.06
28	S	180°	-0.18
29	S	280°	-0.18
30	T	20°	-0.05
31	N	120°	-0.78
32	V	220°	1.08
33	G	320°	0.48
34	S	60°	-0.18
35	N	160°	-0.78
36	T	260°	-0.05
37	Y	0°	0.26

Results by area

Amylin, human (islet amyloid polypeptide) results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

No study has results about Amylin, human (islet amyloid polypeptide) yet.

No study with a publication year is linked to this peptide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

No study of Amylin, human (islet amyloid polypeptide) has results in PepBank yet.

Trials and papers

Amylin, human (islet amyloid polypeptide) trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

0 studies match. Retracted studies are left out.

No study matches these filters.

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Amylin, human (islet amyloid polypeptide) studies: 0 papers with results

No paper with results is linked to this peptide.

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	openFDA Drugs@FDA returned no application with amlintide as active ingredient. Pramlintide (Symlin, NDA021332, approved 2005-03-16) is a different amylin analogue; openFDA lists Symlin as Discontinued.	9 Oct 2026	Not recorded
EU	EMA	No entry in EMA medicines data (report timestamp 2026-10-09T06:23:44Z) and no EU orphan designation.	9 Oct 2026	Not recorded
Sport	WADA	Not named on the List; S0 may still apply (no approval anywhere) S0 bans any substance that has no approval for human use. Amylin, human (islet amyloid polypeptide) has no approval in the sources used, so S0 may apply although the List does not name it.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

Reported effects from study results.

No study results yet

No safety results yet. That does not mean the peptide is safe.

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000037
Peptide version: 8
Peptide hash: 45c44bd506494b80…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256638
22 Oct 2026UpdatedData version 254488
21 Oct 2026UpdatedData version 213593
14 Oct 2026UpdatedData version 194675
13 Oct 2026UpdatedData version 173525
12 Oct 2026UpdatedData version 165100

For developers

curl -s https://pepbank.io/v1/briefs/amylin

Evidence summary for Amylin, human (islet amyloid polypeptide): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Amylin, human (islet amyloid polypeptide) studies and research data

Amylin, human (islet amyloid polypeptide) identity

Targets

Sequence and structure

Sequence

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

Amylin, human (islet amyloid polypeptide) results by year and outcome

What the studies measured

Amylin, human (islet amyloid polypeptide) trials

Papers

Newer studies

Amylin, human (islet amyloid polypeptide) studies: 0 papers with results

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

Amylin, human (islet amyloid polypeptide) results by year and outcome

Amylin, human (islet amyloid polypeptide) trials

Papers

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers